Skip to main content
Unichem Laboratories Ltd. logo

Unichem Laboratories Ltd. — Investor Relations & Filings

Ticker · UNICHEMLAB ISIN · INE351A01035 LEI · 3358008AHXLO9H4C2Q20 BSE.NS Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2022-01-10 Regulatory Filings
Country IN India
Listing BSE.NS UNICHEMLAB

About Unichem Laboratories Ltd.

https://www.unichemlabs.com/

Unichem Laboratories Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company provides solutions across various therapeutic areas, including cardiology, gastroenterology, anti-infectives, diabetology, orthopedics, and neurology. It maintains a significant international footprint, exporting products to regulated markets such as the United States and Europe. The manufacturing infrastructure is built to comply with global standards, featuring approvals from international regulatory agencies. Through its dedicated research and development initiatives, the organization develops a robust pipeline of generic products and complex formulations aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings
2022-01-10 English
Compliance Certificate under regulation 74[5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021.
Regulatory Filings
2022-01-10 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice regarding the closure of the trading window for insiders and designated persons around the release of quarterly financial results. It references compliance with insider trading regulations and specifies the trading window will close from January 1, 2022, until 48 hours after the financial results for the quarter and nine months ended December 31, 2021, are made public. The document does not contain any financial data, detailed report, or results itself, but is a regulatory announcement related to trading restrictions. It is short (1495 characters) and serves as a formal notification to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-12-31 English
Closure of Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice regarding the closure of the trading window for insiders and designated persons in compliance with insider trading regulations. It references the upcoming financial results for the quarter and nine months ended December 31, 2021, but does not contain any financial data or results itself. It is a regulatory compliance announcement related to insider trading restrictions rather than a financial report or earnings release. The document length is short (1495 characters) and it serves as a formal notification to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-31 English
Updates
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the receipt of ANDA approval from the USFDA for a pharmaceutical product. It is an update on a regulatory approval event and does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (3459 characters) and serves as an announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing in the sense of compliance documents or certifications. The best fitting category is Capital/Financing Update (CAP) since it relates to a significant business development impacting the company's product portfolio and potential revenue streams, which is typical for such announcements. Confidence is high given the clear nature of the document as a press release about regulatory approval and business update.
2021-12-02 English
ANDA approval for Aripiprazole Tablets
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of ANDA approval from the USFDA for a pharmaceutical product. It is an update on a regulatory approval event and does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (3459 characters) and serves as a notification to stock exchanges under SEBI regulations. It is not an annual report, earnings release, or any detailed financial or governance report. It fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-12-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.